11.1
薬学的同等性
規制基準の定義によれば、薬学的同等性とは、ジェネリック医薬品が同一の剤形と化学的に同一のAPIを有することを求めるものです。力価、含量均一性、崩壊時間、溶出速度については、公定書または適用可能な基準を遵守しなければなりません。放出制御型剤形の場合には、投与されるAPI量が先発医薬品と一致している限り…
医薬品同等物は、同様の投与期間で同じ量の医薬品有効成分または API を提供します。
ジェネリック医薬品は、同量の医薬品有効成分を含み、同じ剤形を有する場合、薬学的に参照医薬品と同等である。
それらは、効力、含有量の均一性、崩壊時間、および溶解速度に関する大略基準を遵守する必要があります。
送達された薬物量がイノベーター製品の量と同じままである場合、放出調節剤形では薬物含有量の変動が許可されます。
ただし、同じ API の異なる塩の形態またはプロドラッグは、FDA の定義では医薬品の同等物とは見なされません。
医薬品的に同等の製品には、異なる賦形剤または許容される不純物が含まれている場合があり、形状、パッケージ、ラベル、および物理的特性も異なる場合があります。
粒子サイズ、多型、純度、安定性、立体化学などの API 特性は、医薬品の同等性に影響を与えます。
ドラッグデリバリーシステム、剤形の物理的特性、無菌性、過剰、および製造プロセスも、その同等性に影響します。
View the full transcript and gain access to JoVE Core videos
Q1: What makes a generic drug pharmaceutically equivalent to a brand-name drug?
A generic drug is pharmaceutically equivalent when it contains the same amount of active pharmaceutical ingredient in the same dosage form as the reference drug. It must meet compendial standards for potency, content uniformity, disintegration time, and dissolution rate. These requirements ensure consistent therapeutic performance across batches.
Q2: Can pharmaceutical equivalents differ in their inactive ingredients?
Yes, pharmaceutically equivalent products may contain different excipients and impurities while maintaining the same active ingredient and dosage form. They can also vary in shape, packaging, and labeling. However, these differences must not affect the drug's bioavailability or therapeutic effectiveness.
Q3: How do particle size and polymorphism affect pharmaceutical equivalence?
Particle size, polymorphism, and other API characteristics like purity and stereochemistry directly influence pharmaceutical equivalence. Different polymorphic forms or particle sizes can alter drug dissolution and absorption rates. These factors must remain consistent with the innovator product to maintain equivalence.
Q4: Are different salt forms of the same API considered pharmaceutical equivalents?
No, different salt forms or prodrugs of the same API do not meet the FDA's definition of pharmaceutical equivalents. Although they contain the same active ingredient, variations in salt form or prodrug structure are considered distinct pharmaceutical entities requiring separate regulatory evaluation.
Q5: What role does the manufacturing process play in pharmaceutical equivalence?
Manufacturing processes, drug delivery systems, sterility, and overage significantly affect pharmaceutical equivalence. The physical attributes of the dosage form, including those influenced by formulation and manufacturing process physical attributes, must align with the innovator product to ensure consistent drug delivery and therapeutic outcomes.
Q6: How are modified-release dosage forms evaluated for pharmaceutical equivalence?
Modified-release dosage forms may have variations in drug content as long as the total delivered drug amount remains identical to the innovator product. This flexibility accommodates different release mechanisms while maintaining therapeutic equivalence and ensuring patients receive consistent drug exposure over the dosing period.
Q7: Why is API stability important for maintaining pharmaceutical equivalence?
API stability affects pharmaceutical equivalence because degradation or changes in the active ingredient compromise the drug's potency and therapeutic effectiveness. Stability influences how the drug performs throughout its shelf life, making it essential that generic products maintain stability profiles equivalent to the innovator drug.